Hemoprostol H-W-2652

  • Email
  • Help
Name of the medicinal productHemoprostol
Opinion holderLinepharma International Limited
Regents Place
338 Euston Road
London NW1 3BT
United Kingdom
Active substance


International non-proprietary name or common name


Pharmaco-therapeutic group

Other gynecologicals

ATC codeG02AD06
Therapeutic indicationHemoprostol is indicated in women of childbearing age for treatment of Post Partum Haemorrhage due to uterine atony in situations where intravenous oxytocin is not available.
Orphan medicinal product designation dateNot applicable

Back to top

Document(s) Language Status First published Last updated Effective Date
Hemoprostol: Withdrawal of the Article 58 scientific opinion - Public statement (English only)   2017-04-26    
Hemoprostol : Summary for the public (English only)   2014-04-10 2017-04-26  
Hemoprostol : Procedural steps taken and scientific information after the authorisation (English only)   2015-07-21 2017-04-26  
Hemoprostol : Risk-management-plan summary (English only)   2014-04-10 2017-04-26  
Hemoprostol : All presentations (English only)   2014-04-10 2017-04-26  
Hemoprostol : Public assessment report (English only) adopted 2014-04-10 2017-04-26  
CHMP summary of positive opinion for Hemoprostol (English only) adopted 2014-01-24 2017-04-26  

Product Information* 26/03/2015 Hemoprostol-H-W-2652-IAIN-0003

Back to top

Document(s) Language Status First published Last updated Effective Date
Hemoprostol : Product Information (English only)   2014-04-10 2017-04-26  

Related links

*This document includes:

Annex I - Summary of product characteristics
Annex IIA - Manufacturer responsible for batch release
Annex IIB - Recommendations to the opinion holder - conditions of use
Annex IIIA - Labelling
Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.